310 related articles for article (PubMed ID: 16829658)
1. BRCA1 and BRCA2 cancer risks.
Antoniou AC; Pharoah PD; Easton DF; Evans DG
J Clin Oncol; 2006 Jul; 24(20):3312-3; author reply 3313-4. PubMed ID: 16829658
[No Abstract] [Full Text] [Related]
2. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
[TBL] [Abstract][Full Text] [Related]
3. One risk fits all?
De Bock GH; Mourits MJ; Oosterwijk JC
J Clin Oncol; 2007 Aug; 25(22):3383-4; author reply 3384. PubMed ID: 17664491
[No Abstract] [Full Text] [Related]
4. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility.
Wolff TA; Wilson JE
Am Fam Physician; 2006 Nov; 74(10):1759-60. PubMed ID: 17137007
[No Abstract] [Full Text] [Related]
5. [BRCA1 and BRCA2 have reached the clinical medicine. The 10-year old finding of the genetic mutation makes it now possible to prevent breast cancer].
Loman N
Lakartidningen; 2004 Jun; 101(25):2172-7. PubMed ID: 15281304
[TBL] [Abstract][Full Text] [Related]
6. Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer.
Spannuth WA; Thaker PH; Sood AK
Am J Obstet Gynecol; 2007 Apr; 196(4):e6-9. PubMed ID: 17403394
[TBL] [Abstract][Full Text] [Related]
7. Towards more effective and equitable genetic testing for BRCA1 and BRCA2 mutation carriers.
James PA; Harris M; Lindeman GJ; Mitchell G
J Med Genet; 2008 Nov; 45(11):765-6. PubMed ID: 18978334
[No Abstract] [Full Text] [Related]
8. Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer.
Forman AD; Hall MJ
Breast J; 2009; 15 Suppl 1():S56-62. PubMed ID: 19775331
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer risks for BRCA1/2 carriers.
Wacholder S; Struewing JP; Hartge P; Greene MH; Tucker MA
Science; 2004 Dec; 306(5705):2187-91; author reply 2187-91. PubMed ID: 15622558
[No Abstract] [Full Text] [Related]
10. Optimal selection of individuals for BRCA mutation testing.
Evans DG; Lalloo F; Eccles D
J Clin Oncol; 2006 Jul; 24(20):3311; author reply 3311-2. PubMed ID: 16829657
[No Abstract] [Full Text] [Related]
11. Cancer risks for Australian women with a BRCA1 or a BRCA2 mutation.
Suthers GK
ANZ J Surg; 2007 May; 77(5):314-9. PubMed ID: 17497966
[TBL] [Abstract][Full Text] [Related]
12. [Inherited breast and ovarian cancers].
Gerdes AM; Ejlertsen B
Ugeskr Laeger; 2006 Jun; 168(24):2367-9. PubMed ID: 16822422
[TBL] [Abstract][Full Text] [Related]
13. Using genetic analysis to individualize preventive measures for breast and ovarian cancers.
Olopade OI
Nat Clin Pract Oncol; 2006 Apr; 3(4):182-3. PubMed ID: 16596140
[No Abstract] [Full Text] [Related]
14. Cancer. A risky business--assessing breast cancer risk.
Levy-Lahad E; Plon SE
Science; 2003 Oct; 302(5645):574-5. PubMed ID: 14576407
[No Abstract] [Full Text] [Related]
15. Hereditary breast-ovarian cancer: clinical findings and medical management.
Marshall M; Solomon S
Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820
[TBL] [Abstract][Full Text] [Related]
16. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Fan I; Tang J; Li S; Zhang S; Shaw PA; Narod SA
J Natl Cancer Inst; 2006 Dec; 98(23):1694-706. PubMed ID: 17148771
[TBL] [Abstract][Full Text] [Related]
17. Cancer risk assessment and the genetic counseling process: using hereditary breast and ovarian cancer as an example.
Prucka SK; McIlvried DE; Korf BR
Med Princ Pract; 2008; 17(3):173-89. PubMed ID: 18408385
[TBL] [Abstract][Full Text] [Related]
18. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
19. Receiving inconclusive genetic test results: an interpretive description of the BRCA1/2 experience.
Maheu C; Thorne S
Res Nurs Health; 2008 Dec; 31(6):553-62. PubMed ID: 18449940
[TBL] [Abstract][Full Text] [Related]
20. Does the search for large genomic rearrangements impact BRCAPRO carrier prediction?
Capalbo C; Buffone A; Vestri A; Ricevuto E; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A; Giannini G
J Clin Oncol; 2007 Jun; 25(18):2632-4; author reply 2634-5. PubMed ID: 17577048
[No Abstract] [Full Text] [Related]
[Next] [New Search]